Skip to main navigation Skip to search Skip to main content

Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient

Research output: Contribution to journal › Journal article › peer-review

Original languageKorean
JournalArchive of Clinical Cases
StatePublished - 2025.01.1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this